Last reviewed 2026-04-23 · How we verify

SYR-472

SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.

SYR-472 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for Solid tumors with FGFR gene fusions or amplifications.

At a glance

Mechanism of action

SYR-472 targets FGFR pathways that are dysregulated in certain cancers, particularly those with FGFR gene fusions or amplifications. By inhibiting FGFR kinase activity, the drug suppresses proliferation of cancer cells driven by these molecular alterations. This mechanism is particularly relevant in solid tumors with specific FGFR genetic alterations.

Approved indications

• Solid tumors with FGFR gene fusions or amplifications

Common side effects

• Hyperphosphatemia
• Diarrhea
• Fatigue
• Nausea
• Stomatitis

Key clinical trials

• Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients (PHASE3)
• Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes (NA)
• Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes (NA)
• Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Severe Renal Impairment or End-stage Renal Disease"
• Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus (PHASE4)
• A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets (PHASE1)
• Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (PHASE4)
• Long-term Study of SYR-472 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.